STALLERGENES-GREER
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into an exclusive partnership with Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, for the development of the first of its kind connected device and companion mobile app for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions.
“This exclusive partnership with Aptar Pharma demonstrates the intensification of Stallergenes Greer’s investments in innovation to provide a large range of precise personalised allergen immunotherapy options adapted to the individual needs and lifestyle of patients. Stallergenes Greer is well advanced on its digital transformation journey and will continue to develop its e-health offering for the benefit of all stakeholders,” stated Dominique Pezziardi, General manager France, Belgium and Luxembourg, Global Head of Pricing and Market Access.
Non-adherence to an AIT schedule and premature discontinuation of treatment remain a challenge in AIT management. This innovative, easy-to-use connected device will contribute to improving dose compliance and adherence, thus optimising treatment outcomes.
The development work is being undertaken by Aptar Pharma’s Digital Health group, which has capabilities and expertise in device and software development. The product will leverage Aptar Pharma’s Cohero platform, which will be tailored specifically for this use.
“We are pleased to combine Aptar Pharma’s Digital Health ecosystem with Stallergenes Greer’s knowledge and leading position in AIT to further improve the treatment journey of patients who suffer from allergies,” said Sai Shankar, Vice President, Global Digital Healthcare Systems, Aptar Pharma.
The newly developed connected device should be available in France in 2022 and will be progressively rolled-out in Stallergenes Greer’s markets.
This innovation further illustrates Stallergenes Greer’s commitment to build on precision medicine and personalised healthcare which cater to the needs of both patients and the medical community.
ABOUT STALLERGENES GREER LTD
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com
ABOUT APTAR PHARMA
Aptar Pharma is part of Aptar Group Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005769/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin Brings Biology Super Intelligence Closer to Reality with New AI Infrastructure for Biological Breakthroughs12.1.2026 18:00:00 CET | Press release
New AI Agents Trained on Millions of Multimodal Datasets Will Speed up Biomedical Research Throughout the Healthcare Ecosystem; Also Announcing New Anthropic Relationship Owkin, the AI company on a mission to solve the complexity of biology, today announced the launch of its agentic infrastructure for biology, making its best-in-class AI agents available to the healthcare ecosystem. The announcement comes at the JPM Healthcare Conference 2026 and follows Owkin’s recent strategic partnerships and its just-announced integration with Claude for Healthcare and Life Sciences by Anthropic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112461277/en/ Owkin, a 10-year-old AI company with $300 million in funding, is introducing the infrastructure, built on a unique advantage: unparalleled, curated, multimodal patient data from diverse geographies, collected from more than 800 hospitals over a decade. While other companies focus pr
Owkin's Specialized Biological AI Agent Pathology Explorer Launches with Anthropic's Claude for Healthcare and Life Sciences12.1.2026 18:00:00 CET | Press release
First Interoperable AI Agent Trained on Multimodal Patient Data is Accessible Through Model Context Protocol (MCP), Bringing State-of-the-Art Agentic AI to the Healthcare Industry Owkin, an AI company on a mission to solve the complexity of biology, today announced that its interoperable Pathology Explorer AI agent will be included in the launch of Claude for Healthcare and Life Sciences (HCLS) by Anthropic. This marks the first time a highly specialized, world-leading biological agent trained primarily on multimodal patient data is accessible through the Model Context Protocol (MCP) to a broad audience of healthcare and life sciences professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112836381/en/ Owkin's Specialized Biological AI Agent Pathology Explorer Launches with Anthropic's Claude for Healthcare and Life Sciences. The collaboration enables seamless integration of Owkin's advanced pathology analysis capa
Berkshire Hathaway Specialty Insurance Names David Lee Global Chief Human Resources Officer12.1.2026 16:27:00 CET | Press release
Berkshire Hathaway Specialty Insurance (BHSI) today announced the promotion of David Lee to Global Chief Human Resources Officer. “I am thrilled to have David leading our human resources group worldwide,” said Peter Eastwood, President and Chief Executive Officer, BHSI. “An experienced HR practitioner and lifelong student of the profession, his deep expertise, stellar work ethic, and commitment to BHSI values will continue to drive success across our global talent and HR initiatives.” David succeeds Kim Briones, who has led BHSI’s HR group since the company’s founding in 2013 and is retiring from her full-time role. “I want to express my sincere gratitude to Kim for her partnership and friendship over many years and for her outstanding leadership in building our HR function from the ground up,” Peter added. “She has played a pivotal role in growing and developing our company’s greatest asset – our global team of individuals with excellent capabilities and strong character – and in help
Owkin Advances Frontier Model Development for Biological Artificial Super Intelligence, Accelerated by NVIDIA12.1.2026 16:00:00 CET | Press release
Collaboration Leverages NVIDIA's Open Models, AI Infrastructure and Expertise to Build Next-Generation Biological Reasoning Models for Drug Development Owkin, an AI company on a mission to solve the complexity of biology, today announced a collaboration with NVIDIA to enhance OwkinZero, Owkin's biological large reasoning model. The collaboration will leverage NVIDIA's advanced AI computing ecosystem, including the Nemotron family of open models and the NVIDIA NeMo framework to improve the performance, scalability, guardrails, and robustness of Owkin's biological reasoning capabilities to accelerate future breakthroughs in drug discovery and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112573701/en/ Owkin Advances Frontier Model Development for Biological Artificial Super Intelligence, Accelerated by NVIDIA. This marks Owkin's first collaboration with NVIDIA and represents a significant milestone in building
SecurityBridge Announces CEO Transition to Accelerate Global Expansion12.1.2026 15:15:00 CET | Press release
SecurityBridge, a leading provider of cybersecurity solutions for SAP, today announced the appointment of Jesper Zerlang as Chief Executive Officer, effective January 1, 2026. Zerlang transitions from his role as Chairman of the Board, a position he has held for the past 12 months, as the company enters its next phase of international expansion, backed by funds advised by BUBregal Unternehmerkapital (BU). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112824449/en/ Jesper Zerlang appointed Chief Executive Officer, SecurityBridge SecurityBridge protects SAP environments for large enterprises by reducing cyber risk across mission-critical SAP landscapes. The company is trusted by global customers to safeguard systems that power core operations, financial processes, supply chains, and digital transformation programs. “SecurityBridge is uniquely positioned at the intersection of cybersecurity and SAP – a domain I know deeply
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom